{"authors":["Tamara Mathias"],"date_download":"2018-10-30 22:34:46","date_modify":"2018-10-30 22:34:46","date_publish":"2018-07-31 00:00:00","description":"Pfizer reported adjusted earnings that topped Wall Street estimates thanks to strong sales of pneumonia vaccine Prevnar and arthritis drug Xeljanz. The drugmaker raised its adjusted earnings forecast, but lowered its revenue forecast.","filename":"data/vaneerConsumption/Pfizerbeatsandraisesitsearningsforecast.json","image_url":"https://amp.businessinsider.com/images/57046a2952bcd05b008baf3b-2732-1366.jpg","language":null,"localpath":"/home/avsp_here/news-please-repo//data/2018/10/30/businessinsider.com/_pfizer-profit-beats-raises-earnings-forecast-2018-7_1540938886.html","title":"Pfizer beats and raises its earnings forecast","title_page":"    Pfizer profit beats, raises earnings forecast - Business Insider\n","title_rss":"NULL","source_domain":"businessinsider.com","text":"REUTERS/Adam Hunger\n(Reuters) - U.S. drugmaker Pfizer Inc posted a better-than-expected quarterly profit on Tuesday, driven by higher sales of pneumonia vaccine Prevnar and arthritis drug Xeljanz.\nThe company lowered its 2018 revenue expectation to between $53 billion and $55 billion, from $53.5 billion to $55.5 billion, due to a strengthening dollar.\nNet income rose to $3.87 billion, or 65 cents per share, in the second quarter, from $3.07 billion, or 51 cents per share, a year earlier.\nExcluding special items, the company earned 81 cents per share, beating analysts' average estimate of 74 cents, according to Thomson Reuters I/B/E/S.\nRevenue rose 4.4 percent to $13.47 billion, ahead of expectations of $13.31 billion.\nThe company raised its full-year adjusted earnings per share forecast to between $2.95 and $3.05, from $2.90 to $3.00 earlier.\nPfizer said the new forecast reflects $6.1 billion worth of share repurchases already completed in 2018.\n(Reporting by Tamara Mathias in Bengaluru; Editing by Sriraj Kalluvila)","url":"https://www.businessinsider.com/pfizer-profit-beats-raises-earnings-forecast-2018-7"}
